Tyme Technologies Inc., (TYME) an emerging biotechnology company, surged 28% to close at $1.38 on July 26.
With a market capitalization of 237.6 million, the share price of Tyme rocketed almost 31.4% in the last five days.
The company develops cancer metabolism-based therapies, known as CMBTs. These medicines are effective against a broad range of solid tumors and hematologic malignancies. (See Tyme stock charts on TipRanks)
Why the Buzz about Tyme?
The recent price hike took place after Tyme received patent notification for its metabolomic technology platform.
The approval came from the U.S. Patent and Trademark Office. The patent covers a “targeted delivery of therapeutics to cancer cells.”
The patent, which is based on Tyme’s technology, allows the tyrosine isomer racemetyrosine to be fused with a second therapeutic substance to generate a fusion product that may allow for unique targeted delivery to cancer cells.
Tyme’s Chief Scientific Officer Steve Hoffman said, “This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs.”
Investors hope that Tyme will be able to use this technology to broaden its present cancer-metabolism-based approach.
After this huge price surge, one might wonder whether the upside will continue… TipRanks’ metrics give us mixed results.
As per TipRanks’ Stock Investors tool, investors have a ‘Very Negative’ outlook on Tyme stock, with 14.1% of investors tracked on TipRanks decreasing their exposure in the last 30 days.
Conversely, TipRanks data shows that financial blogger opinions are 100% Bullish, compared to a sector average of 71%.
Tyme’s Risk Factors
To get more clarity on the stock, we could look into the company’s risk factors.
According to the new Tipranks Risk Factors tool, Tyme’s main risk category is Tech & Innovation, which accounts for 34% of the total 67 risks identified. The next two major risk factor contributors are Finance & Corporate and Legal & Regulatory, which stand at 24% and 19%, respectively.
Since December 2020, Tyme has added one new risk factor under the Finance & Corporate category.
Under the above-mentioned category, Tyme highlights that a recent review of the company’s product portfolio and development strategy could result in major changes, impacting the company’s financials.
The risk factors show the challenges a company faces so that investors can consider the worst-case scenarios before making an investment in this company.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
